We offer a unique screening file with high quality proprietary and commercial compounds for screening which are designed and selected using the patented EligoChem approach. All compounds are amphiphilic in nature, with proven enhanced absorption and reduced poly-pharmacology risk and have excellent potential for successful optimisation as leads and progression into drug candidates. These properties deliver compounds in a lower polarity and MW range to conventional hit and lead compounds providing discovery teams with unique starting points for further optimisation using modular synthesis approaches.
The graphs below demonstrate the physicochemical properties of EligoChem compound libraries, compared to a typical screening collection.
Non Proprietary Compound Collection
This collection of 1050 compounds have been carefully selected from available commercial compounds, and have all been shown to have desirable amphiphilic character with our proprietary work flows. These compounds can be further segmented into MW and logP clusters as required and also include larger molecules that maybe useful when screening for disruptors of protein-protein interactions.
Virtual Compound Library
Our virtual library of 100,000 novel amphiphilic compounds is constructed from a carefully selected set of heterocyclic ‘scaffolds/cores’ and ‘monomers’ and any of which can be synthesised to order.
Original Scaffold Collection
This physical collection of 250+ compounds has been synthesised and incorporates compounds selected from the Virtual Compound Library above and has been used in key proof of concept studies to further underpin the EligoChem amphiphilic approach.
Types of Target
The EligoChem screening library is suited to any target, as it markedly increases screening diversity but is particularly suited to:
- Cell Based Assays – Good cellular absorption
- Protein-Protein Interactions – High hydrogen bonding potential
- Antibiotic Targets – Good overlap with chemical properties of known antibiotics
For more information on our libraries, please contact us directly.